Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the closing of an oversubscribed Series B financing, which raised $162 million. The financing was led by Boxer Capital of Tavistock Group, EcoR1 Capital, LLC, Omega Funds and Vida Ventures, with participation from new investors Surveyor Capital (a Citadel company), Invus, Wellington Management Company, Nextech Invest, OrbiMed, Casdin Capital, LLC, Woodline Partners LP, Logos Capital, Janus Henderson Investors and other undisclosed institutional investors, as well as existing investors Atlas Venture and Abingworth. With this financing, Scorpion has raised approximately $270 million since the company was founded in the first quarter of 2020.